These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 23801808)

  • 1. Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.
    Home PD
    Diabetes Care; 2013 Jul; 36(7):e106. PubMed ID: 23801808
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.
    Bergenstal RM; Rosenstock J; Arakaki RF; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
    Diabetes Care; 2013 Jul; 36(7):e107-8. PubMed ID: 23801809
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
    Bergenstal RM; Rosenstock J; Arakaki RF; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
    Diabetes Care; 2012 Nov; 35(11):2140-7. PubMed ID: 22787177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
    Rosenstock J; Bergenstal RM; Blevins TC; Morrow LA; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
    Diabetes Care; 2013 Mar; 36(3):522-8. PubMed ID: 23193209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
    Owens DR; Matfin G; Monnier L
    Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
    Standl E; Owen DR
    Diabetes Care; 2016 Aug; 39 Suppl 2():S172-9. PubMed ID: 27440830
    [No Abstract]   [Full Text] [Related]  

  • 9. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
    Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ
    Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683
    [No Abstract]   [Full Text] [Related]  

  • 10. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
    Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
    Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin glargine dosing before next-day surgery: comparing three strategies.
    Rosenblatt SI; Dukatz T; Jahn R; Ramsdell C; Sakharova A; Henry M; Arndt-Mutz M; Miller V; Rogers K; Balasubramaniam M
    J Clin Anesth; 2012 Dec; 24(8):610-7. PubMed ID: 23122972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
    Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
    Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials.
    Esposito K; Chiodini P; Capuano A; Petrizzo M; Improta MR; Giugliano D
    Diabetes Care; 2012 Dec; 35(12):2698-705. PubMed ID: 23173139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2016 Mar; 66(3):360-1. PubMed ID: 26968297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
    Yoshihara T; Kumashiro N; Kanazawa Y; Mita T; Sakurai Y; Kawai J; Abe M; Motojima K; Hara K; Yamazaki Y; Kanazawa A; Miwa S; Sato F; Kanno R; Shimizu T; Sakai K; Uchino H; Watada H; Tanaka Y; Kawamori R; Hirose T
    Endocr J; 2006 Feb; 53(1):67-72. PubMed ID: 16543674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
    Dhital SM; Shenker Y; Meredith M; Davis DB
    Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
    Hamid Z; Simmons DL
    Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.